Astellas Pharma Inc
ASTPM
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
1067 / 1328
Position in country
4536 / 4811
Return on Assets, %
-0.1
-2.7
Net income margin, %
3.4
2.8
EBITDA margin, %
17
10.8
Debt to Equity, %
57.9
19.2
Intangible assets and goodwill, %
54.6
3.6
Revenue CAGR 3Y, %
5.2
8.5
Total Equity change 1Y, %
-11.1
0
Revenue Y, % chg
-1.2
0.5
P/E
636.2
22.7
P/BV
1.8
1.5
P/S
1.8
2.3
EV/S
2.2
2.4
EV/EBITDA
15.4
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
44.5
51.3
Forward P/E
20.9
15.6
Dividend Yield, %
4.3
1.7
Payout Ratio, %
2800.8
30.3
Competitors
Ranks
-
Daiichi Sankyo Co Ltd
00%
-
Ono Pharmaceutical Co Ltd
00%
-
Kyowa Kirin Co Ltd
00%
-
Shionogi & Co Ltd
00%
-
Taisho Pharmaceutical Holdings Co Ltd
00%
-
Chugai Pharmaceutical Co Ltd
00%
-
Takeda Pharmaceutical Co Ltd
00%
-
Eisai Co Ltd
00%
-
Otsuka Holdings Co Ltd
00%
-
Astellas Pharma Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Japan
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
18548.8
Ticker
ALPMY.PK
ISIN
US04623U1025
IPO date
1949-05-16
Availability on Russian exchanges
No
Reporting for
2024-02-06
Date fact. publication of reports
2023-12-31
Company Description
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: